Skip to main content
. 2021 Jun 9;10(12):2548. doi: 10.3390/jcm10122548

Table 2.

Proposed treatments in 58 anti-MPO-ILD patients.

n %
Azathioprine 11 20.7
Cyclophosphamide 4 7.5
Mycophenolate 8 15.1
Rituximab 3 5.7
No immunosuppressors 31 58.5
1 immunosuppressor 19 35.8
2 immunosuppressors 2 3.8
3 immunosuppressors 1 1.9
Pirfenidone 8 15.1
Nintedanib 5 9.4
Steroids 34 64.1
O2 supplementation 18 34